| Drug Name | (Triumeq®(DOLUTEGRAVIR, ABACAVIR, LAMIVUDINE |
|---|---|
| Drug Class |
Anti-viral
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Infectious disease
|
| Risk |
Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception, in Tsepamo Study, Botswana |
| Dear Healthcare provider letter DHPC |
|